Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 July 2020Website:
http://www.alxoncology.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
ALXO Latest News
Analysts' price targets for ALX Oncology Holdings (ALXO) suggest a potential 36.6% increase in the stock. Although this metric is not always reliable, the consensus among analysts in increasing earnings estimates does indicate a positive outlook for the stock.
ALX Oncology (ALXO) reports encouraging findings from a phase 1/2 trial of a potential combination therapy for the treatment of refractory or relapsed B-cell non-Hodgkin lymphoma, including both indolent and aggressive forms.
As we head into 2024, it's common for investors to look back on 2023. Much of this year had investors in a defensive posture.
ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastroesophageal junction cancer. Final results from the ASPEN-06 study are expected to be released in Q2 2024, potentially leading to further gains for investors. ALXO also announced a cash raise of $55 million, reducing the need for a future cash raise and lowering the risk of dilution.
Interim data from a mid-stage study shows that a combination regimen of ALX Oncology's (ALXO) lead candidate achieved 52% ORR in certain gastric cancer patients.
ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing the potential of its lead asset in cancer of the stomach and esophagus. The ASPEN-06 clinical evaluated the effectiveness of evorpacept in treating patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.
ALX Oncology Holdings Inc. (ALXO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
What type of business is ALX Oncology Holdings?
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
What sector is ALX Oncology Holdings in?
ALX Oncology Holdings is in the Healthcare sector
What industry is ALX Oncology Holdings in?
ALX Oncology Holdings is in the Biotechnology industry
What country is ALX Oncology Holdings from?
ALX Oncology Holdings is headquartered in United States
When did ALX Oncology Holdings go public?
ALX Oncology Holdings initial public offering (IPO) was on 17 July 2020
What is ALX Oncology Holdings website?
https://www.alxoncology.com
Is ALX Oncology Holdings in the S&P 500?
No, ALX Oncology Holdings is not included in the S&P 500 index
Is ALX Oncology Holdings in the NASDAQ 100?
No, ALX Oncology Holdings is not included in the NASDAQ 100 index
Is ALX Oncology Holdings in the Dow Jones?
No, ALX Oncology Holdings is not included in the Dow Jones index
When does ALX Oncology Holdings report earnings?
The next expected earnings date for ALX Oncology Holdings is 09 August 2024